Skip to content
Search

Latest Stories

Bank Of Baroda, Vijaya Bank, Dena Bank Share Swap Ratio Approved

India’s Bank of Baroda (BoB) approved the swap ratio for the planned merger of Vijaya Bank and Dena Bank with itself, according to an exchange filing on Wednesday (02).

The board of directors of the BoB approved the swap ratio for the amalgamation. Accordingly, Vijaya Bank shareholders will get 402 shares of BoB for 1,000 shares held of Vijaya Bank. Dena Bank shareholders will obtain 110 shares of BoB for every 1,000 shares.


A grievance redressal committee headed by Mumbai High Court retired judge Kode, has been set up to address the grievances of minority shareholders, BoB said.

Last year, the Indian government announced the merger of Vijaya Bank and Dena Bank with the BoB. The merged entity will be the third-largest bank after State Bank of India and HDFC Bank in India.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less